Cantor Fitzgerald Predicts uniQure FY2026 Earnings

uniQure (NASDAQ:QURE - Free Report) - Cantor Fitzgerald issued their FY2026 earnings per share estimates for uniQure in a report issued on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska forecasts that the biotechnology company will post earnings of ($1.99) per share for the year. Cantor Fitzgerald currently has a "Strong-Buy" rating on the stock. The consensus estimate for uniQure's current full-year earnings is ($3.75) per share.

uniQure (NASDAQ:QURE - Get Free Report) last posted its quarterly earnings results on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share for the quarter, topping analysts' consensus estimates of ($1.07) by $0.25. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The business had revenue of $1.57 million for the quarter, compared to analysts' expectations of $5.93 million.

Other equities research analysts have also issued research reports about the company. Guggenheim reissued a "buy" rating and set a $28.00 price target on shares of uniQure in a research note on Monday, May 12th. Wells Fargo & Company reduced their price objective on uniQure from $35.00 to $30.00 and set an "equal weight" rating for the company in a report on Friday, February 28th. Chardan Capital reiterated a "buy" rating and set a $38.00 target price on shares of uniQure in a research report on Friday, May 30th. Wall Street Zen raised uniQure from a "sell" rating to a "hold" rating in a report on Saturday, May 24th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $70.00 price target on shares of uniQure in a research note on Thursday, May 29th. Four equities research analysts have rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $37.82.

uniQure Price Performance

QURE traded down $0.65 on Tuesday, hitting $15.34. 740,185 shares of the company were exchanged, compared to its average volume of 1,924,238. uniQure has a fifty-two week low of $3.73 and a fifty-two week high of $19.18. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. The firm has a market capitalization of $840.26 million, a P/E ratio of -3.09 and a beta of 0.08. The business's fifty day moving average is $13.45 and its 200 day moving average is $13.48.

Institutional Trading of uniQure

Several hedge funds and other institutional investors have recently added to or reduced their stakes in QURE. Twin Tree Management LP purchased a new stake in uniQure in the fourth quarter valued at approximately $77,000. Mraz Amerine & Associates Inc. acquired a new position in shares of uniQure in the 1st quarter valued at $106,000. OMERS ADMINISTRATION Corp purchased a new stake in shares of uniQure during the 1st quarter valued at $152,000. ADAR1 Capital Management LLC acquired a new stake in shares of uniQure during the 4th quarter worth $177,000. Finally, Wells Fargo & Company MN increased its holdings in shares of uniQure by 13.9% during the 4th quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company's stock worth $217,000 after buying an additional 1,503 shares during the last quarter. Hedge funds and other institutional investors own 78.83% of the company's stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.